EQT Fund Management S.a r.l.

Fundamental diversified ★Signal CIK 1834239
Long book
$1.02B
Q1 2026
Positions
5
Top-10 weight
100%
concentration
Last quarter
-10.7%
SPY +14.8%
Turnover
20%
of book per quarter

Strategy in plain words

auto-generated from filings

EQT Fund Management S.a r.l. is a diversified fundamental manager, running a $1.02B US long book across 5 positions.

The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: WAYSTAR HOLDING CORP, OCULIS HOLDING AG, EVOMMUNE INC, PHARVARIS NV, AGOMAB THERAPEUTICS NV.

We rate its filings as signal-bearing: position changes reflect genuine views.

Implied long-book return vs S&P 500

methodology: positions priced quarterly, no shorts/options
Fund long book S&P 500
Q3 2025
-4.6%
Q4 2025
-13.1%
Q1 2026
-10.7%

Sector allocation

Technology
62%
Healthcare
38%

Long book by quarter

$1.86B
Q3 2025
$1.11B
Q4 2025
$1.02B
Q1 2026

What does EQT Fund own?

Q1 2026 13F
CompanySectorSharesValue% of bookChange
WAY WAYSTAR HOLDING CORPTechnology24.9M$599.8M58.8%Held
OCS OCULIS HOLDING AGHealthcare5.9M$156.9M15.4%Held
EVMN EVOMMUNE INCHealthcare4.9M$113.3M11.1%Held
PHVS PHARVARIS NVHealthcare3.4M$96.7M9.5%Held

13F filing history

PeriodFormFiledEntriesReported valueFlagsSource
Q1 202613F-HRMay 14, 20265$1.02B canonicalSEC ↗
Q4 202513F-HRFeb 11, 20264$1.11B canonicalSEC ↗
Q3 202513F-HRNov 14, 20254$1.86B canonicalSEC ↗